- Home
- GITS vs ARTL Comparison
GITS vs ARTL Comparison
Compare GITS & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- ARTL
- Stock Information
- Founded
- GITS 2018
- ARTL 2011
- Country
- GITS South Korea
- ARTL United States
- Employees
- GITS N/A
- ARTL 6
- Industry
- GITS
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- ARTL Health Care
- Exchange
- GITS Nasdaq
- ARTL Nasdaq
- Market Cap
- GITS 7.2M
- ARTL 8.4M
- IPO Year
- GITS N/A
- ARTL N/A
- Fundamental
- Price
- GITS $1.80
- ARTL $4.14
- Analyst Decision
- GITS
- ARTL Buy
- Analyst Count
- GITS 0
- ARTL 2
- Target Price
- GITS N/A
- ARTL $30.00
- AVG Volume (30 Days)
- GITS 153.8K
- ARTL 69.0K
- Earning Date
- GITS 11-19-2025
- ARTL 11-11-2025
- Dividend Yield
- GITS N/A
- ARTL N/A
- EPS Growth
- GITS N/A
- ARTL N/A
- EPS
- GITS N/A
- ARTL N/A
- Revenue
- GITS $29.00
- ARTL N/A
- Revenue This Year
- GITS N/A
- ARTL N/A
- Revenue Next Year
- GITS N/A
- ARTL N/A
- P/E Ratio
- GITS N/A
- ARTL N/A
- Revenue Growth
- GITS N/A
- ARTL N/A
- 52 Week Low
- GITS $0.87
- ARTL $3.91
- 52 Week High
- GITS $9.78
- ARTL $28.60
- Technical
- Relative Strength Index (RSI)
- GITS 33.44
- ARTL 34.69
- Support Level
- GITS $2.00
- ARTL $3.94
- Resistance Level
- GITS $2.33
- ARTL $4.54
- Average True Range (ATR)
- GITS 0.16
- ARTL 0.35
- MACD
- GITS -0.03
- ARTL 0.06
- Stochastic Oscillator
- GITS 30.21
- ARTL 20.88
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.